Inhibikase Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Fund move
Fund move
Inhibikase Therapeutics, Inc.
1.53
No thesis.
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Sands Capital VenturesSands Capital Ventures | $26.4M | 10.86% | 0.00% | |
| 2 | Soleus Capital ManagementSoleus | $22.1M | 9.07% | 0.00% | |
| 3 | Trails Edge Capital PartnersTrails Edge Capital Partners | $18.4M | 7.55% | +12.34% | |
| 4 | Fairmount Funds ManagementFairmount Funds | $17.5M | 7.19% | 0.00% | |
| 5 | BlackRockBlackRockindex-like | $15.8M | 6.48% | +23.24% | |
| 6 | ADAR1 Capital ManagementADAR1 | $15.0M | 6.16% | +11.82% | |
| 7 | Blackstone GroupBlackstone | $12.1M | 4.95% | 0.00% | |
| 8 | SirenSiren | $11.9M | 4.88% | 0.00% | |
| 9 | Commodore CapitalCommodore Capital | $11.0M | 4.50% | 0.00% | |
| 10 | Vanguard Capital ManagementVanguardindex-like | $10.0M | 4.12% | +10.89% | |
| 11 | Millennium ManagementMillennium | $8.2M | 3.36% | +37.57% | |
| 12 | Saturn V Capital ManagementSaturn V | $7.9M | 3.23% | +0.15% | |
| 13 | Kalehua Capital ManagementKalehua | $7.8M | 3.19% | +43.00% | |
| 14 | Spruce Street CapitalSpruce Street Capital | $7.3M | 2.99% | 0.00% | |
| 15 | Squadron Capital ManagementSquadron | $6.1M | 2.50% | −14.29% | |
| 16 | Nantahala Capital ManagementNantahala | $5.5M | 2.25% | 0.00% | |
| 17 | Geode Capital ManagementGeodeindex-like | $5.3M | 2.17% | +20.13% | |
| 18 | Stonepine Capital ManagementStonepine | $5.0M | 2.06% | +157.90% | |
| 19 | State StreetState Streetindex-like | $3.9M | 1.59% | +13.24% | |
| 20 | SummitTX CapitalSummitTX Capital | $3.6M | 1.48% | +16.77% | |
| 21 | Integral Health Asset ManagementIntegral Health | $2.7M | 1.13% | 0.00% | |
| 22 | Northern TrustNorthern Trustindex-like | $1.8M | 0.73% | +22.23% | |
| 23 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $1.6M | 0.68% | +31.04% | |
| 24 | Two Sigma InvestmentsTwo Sigma | $1.6M | 0.67% | −4.88% | |
| 25 | Sphera Funds ManagementSphera Funds | $1.3M | 0.54% | new |
105 managers report $243.4M of Inhibikase Therapeutics on form 13F for the quarter ended Jun 30 '26. 15 of them hold 80% of it; Sands Capital Ventures is largest at 10.86%.
Expected move
No implied move.
No implied move.
No implied move.